Overview

This trial is active, not recruiting.

Condition frail in hiv population
Treatment fried scale for frailty assessement
Sponsor Assistance Publique Hopitaux De Marseille
Start date August 2012
End date March 2015
Trial size 510 participants
Trial identifier NCT02874118, 2011-41, 2011-A01679-32

Summary

The frailty and frail elderly was defined in 2001 by Fried as a physiological state of heightened vulnerability to external shocks. 5 criteria for classifying the elderly in 3 categories: frail, pre-frail and not frail. The prevalence of frailty in the general population was estimated to be 7%, 10% and 20% for over 65 years and 45% for over 85 years. This concept is explored in some chronic diseases, in order to prevent the loss of autonomy and tailor the treatment. In the carrier population of HIV, a North American retrospective study showed the frailty syndrome manifested as early as 10 years before, than in the general population. Furthermore various studies show in this specific population, increased incidence of diseases linked to age, suggesting an accelerated and premature aging.

objectives: The objective of this study is to determine the prevalence of frailty defined Fried syndrome in a population of subjects aged 50 and over Holders of chronic HIV infection.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose prevention
Arm
(Experimental)
fried scale for frailty assessement

Primary Outcomes

Measure
Number of frailed patient among the HIV population folloxed in southeastern France area
time frame: one year

Eligibility Criteria

Male or female participants at least 50 years old.

Inclusion Criteria: - Patient with HIV and followed in the southeastern France area Exclusion Criteria: - In patient HIV infected patient - HIV patient disabled (spastic) - HIV infected for less than a year

Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille.